Study of S-1 for Colorectal Cancer
Author Information
Author(s): Van den Brande J, Schöffski P, Schellens J H M, Roth A D, Duffaud F, Weigang-Köhler K, Reinke F, Wanders J, de Boer R F, Vermorken J B, Fumoleau P
Primary Institution: EORTC Early Clinical Studies Group
Hypothesis
Does S-1 provide an effective treatment for patients with advanced or metastatic colorectal cancer?
Conclusion
S-1 is active in patients with advanced colorectal cancer, but it is associated with a high incidence of severe diarrhea.
Supporting Evidence
- S-1 showed a response rate of 24% in evaluable patients.
- Diarrhea was a significant side effect, with 38% of patients experiencing grade 3-4 diarrhea at the higher dose.
- The study included 47 patients treated across six centers.
Takeaway
This study tested a new medicine called S-1 for people with serious colon cancer, and while it helped some patients, many had bad stomach problems.
Methodology
This was a nonrandomised phase II study to determine the response rate of S-1 as first-line treatment for advanced colorectal cancer.
Potential Biases
Potential bias due to nonrandomised design and the subjective nature of response assessment.
Limitations
The study was nonrandomised and had a small sample size, which may limit the generalizability of the results.
Participant Demographics
Patients included were adults aged 18 and older with histologically or cytologically verified metastatic and/or locally advanced colorectal cancer.
Statistical Information
Confidence Interval
(2.3–34.4)
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website